drugset

drugset / Trial / NCT02625558

Riociguat for Sarcoidosis Associated Pulmonary Hypertension

NCT02625558 ↗

Phase 4 Unknown 60 enrolled University of Cincinnati

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary hypertension

Timeline

Start: 2015-04
Primary completion: 2018-04
Completion: 2018-10

Publications

Baughman RP, Shlobin OA, Gupta R, Engel PJ, Stewart JI, Lower EE, Rahaghi FF, Zeigler J, Nathan SD. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial. Chest. 2022 Feb;161(2):448-457. doi: 10.1016/j.chest.2021.07.2162. Epub 2021 Aug 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Riociguat	Other / unclassified	2.5 mg	Oral

Indications